A Study of LY3437943 in Participants With Impaired and Normal Liver Function

A Parallel-Group, Single-Dose, Phase 1, Open-Label Study to Investigate the Pharmacokinetics of LY3437943 in Participants With Hepatic Impairment Compared With Healthy Participants

The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to healthy participants with normal liver function. The safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks for each participant including the screening period.

Inclusion Criteria:

All Participants:

• Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²), inclusive
• Healthy or various degrees of hepatic impairment depending on the study group

Exclusion Criteria:

Participants with hepatic impairment:

• Have or are anticipating an organ transplant within the next 6 months
• Requires needle evacuation of ascites fluid more than 2 times per month
• Have had variceal bleeding within 3 months of check-in, unless the participant has undergone a successful banding procedure; in that case, may check-in from 1 month after the banding procedure